Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Ipecac alternatives

This article was originally published in The Tan Sheet

Executive Summary

The American Academy of Pediatrics states it is "premature to recommend the administration of activated charcoal" as an alternative to ipecac syrup to treat ingestion of a potentially poisonous substance in a Nov. 3 1policy statement. Charcoal is "poorly accepted by young children" and does not store well in the home, the statement says. However, AAP adds that ipecac should "no longer be used routinely as a home treatment strategy" either. The use of activated charcoal in conjunction with ipecac syrup was discussed at Nonprescription Drugs Advisory Committee's June 2003 meeting on retaining ipecac's current OTC status (2"The Tan Sheet" June 2, 2003, p. 5)...

You may also be interested in...



Ipecac Labeling Should Include Maximum Dose – NDAC Briefing Materials

It would be "useful" for the labeling of ipecac syrup to include "a specific time interval for administering activated charcoal after ipecac ingestion," Center for Drug Evaluation & Research Division of Drug Risk Evaluation Safety Evaluator Lauren Lee states in a post-marketing safety review on the emetic syrup

US FDA Gene Therapy Accelerated Approval Guidance Will Describe ‘Buckets’ Of Use Scenarios

Forthcoming guidance is expected to describe areas of “low-hanging fruit” and those that are more challenging for use of the expedited pathway, Center for Biologics Evaluation and Research Director Peter Marks said.

FTC Early Findings In PBM Investigation Coming By Mid-Summer, Chair Kahn Says

The agency is also poised to announce another development in its scrutiny of the drug patents listed in the FDA’s Orange Book.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS096141

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel